Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hauschild

Showing results (1051-1060 of 1,351) with videos related to

Pageof 136
Sort By:
Marine Drugs|December 4, 2020
Efficacy and Mechanism of Action of Marine Alkaloid 3,10-Dibromofascaplysin in Drug-Resistant Prostate Cancer CellsSergey A Dyshlovoy, Moritz Kaune, Jessica Hauschild, et al.
Proteomics|March 23, 2016
Anti-migratory activity of marine alkaloid monanchocidin A - proteomics-based discovery and confirmationSergey A Dyshlovoy, Simone Venz, Jessica Hauschild, et al.
Journal of Animal Science|January 7, 2026
Preventive-curative functional amino acid-supplemented diet improves health, growth performance, and resilience of growing pigs under an immune challengeIsmael França, Danilo Alves Marçal, Graziela Alves Da Cunha Valini, et al.
Annals of Surgical Oncology|April 18, 2014
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)Bernd Gerber, Gunter von Minckwitz, Holger Eidtmann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
Journal of Medical Internet Research|February 2, 2021
Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model StudyMax Schmitt, Roman Christoph Maron, Achim Hekler, et al.
Medicine|November 19, 2016
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapyKatharina C Kaehler, Christine Blome, Andrea Forschner, et al.
Journal of Thoracic Disease|March 20, 2024
Myocardial protection: comparing histological effects of single-dose cardioplegic solutions-study protocol for a secondary analysis of the CARDIOPLEGIA trialKathize Betti Lira, Renan Senandes Delvaux, Felipe Abatti Spadini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2014
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazineJ-J Grob, M M Amonkar, S Martin-Algarra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2016
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trialT K Eigentler, R Gutzmer, A Hauschild, et al.
Pageof 136

Showing results (1051-1060 of 1,351) with videos related to

Sort By:
Pageof 136
Marine Drugs|December 4, 2020
Efficacy and Mechanism of Action of Marine Alkaloid 3,10-Dibromofascaplysin in Drug-Resistant Prostate Cancer CellsSergey A Dyshlovoy, Moritz Kaune, Jessica Hauschild, et al.
Proteomics|March 23, 2016
Anti-migratory activity of marine alkaloid monanchocidin A - proteomics-based discovery and confirmationSergey A Dyshlovoy, Simone Venz, Jessica Hauschild, et al.
Journal of Animal Science|January 7, 2026
Preventive-curative functional amino acid-supplemented diet improves health, growth performance, and resilience of growing pigs under an immune challengeIsmael França, Danilo Alves Marçal, Graziela Alves Da Cunha Valini, et al.
Annals of Surgical Oncology|April 18, 2014
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)Bernd Gerber, Gunter von Minckwitz, Holger Eidtmann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
Journal of Medical Internet Research|February 2, 2021
Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model StudyMax Schmitt, Roman Christoph Maron, Achim Hekler, et al.
Medicine|November 19, 2016
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapyKatharina C Kaehler, Christine Blome, Andrea Forschner, et al.
Journal of Thoracic Disease|March 20, 2024
Myocardial protection: comparing histological effects of single-dose cardioplegic solutions-study protocol for a secondary analysis of the CARDIOPLEGIA trialKathize Betti Lira, Renan Senandes Delvaux, Felipe Abatti Spadini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2014
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazineJ-J Grob, M M Amonkar, S Martin-Algarra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2016
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trialT K Eigentler, R Gutzmer, A Hauschild, et al.
Pageof 136